Brief: Lupin Enters Settlement And License Agreement With Astellas
10/02/2026 02:18
Feb 10 (Reuters) - Lupin Ltd LUPN.NS: ENTERS SETTLEMENT AND LICENSE AGREEMENT WITH ASTELLAS TO PAY ASTELLAS $90 MILLION PREPAID PER UNIT LICENSE FEE FOR EACH UNIT SOLD FROM SETTLEMENT THROUGH SEPTEMBER 2027 Source text: ID:nNSE1RKHf2 Further company coverage: LUPN.NS ((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn